Active — Not RecruitingNot Applicable

Primary Cervical Cancer Screening by Self-sampling HPV Test

China17,875 participantsStarted 2022-11-19

Plain-language summary

Cervical cancer seriously threatens women's health and HPV infection is the main cause of cervical cancer. Traditionally, Cervical cancer screening is based on cervical exfoliated cell samples collected by health care provider, which is labor consuming and the coverage and compliance are both relatively low in some areas. Non-invasive hrHPV self-sampling test appears to be more acceptable and may improve the HPV screening coverage. This study aims to evaluate the clinical performance of a newly developed urine/vaginal self-sampling hrHPV test in Cervical cancer screening.

Who can participate

Age range21 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Known pregnant subjects.
✕. Participants who have undergone total hysterectomy.
✕. Participants who have received cervical resection therapy or ablative therapy within 12 months, such as cryo, laser, microwave, coagulation, cryotherapy, LEEP, large loop electrosurgery (LLETZ), cold knife conization (CKC), laser conization, or ablation.
✕. Participants with poor compliance or researchers who believe that they are not suitable to participate in this study.
✕. Known pregnant subjects.
✕. Participants who have undergone total hysterectomy.
✕. Participants who have received cervical resection therapy or ablative therapy within 12 months, such as cryo, laser, microwave, coagulation, cryotherapy, LEEP, large loop electrosurgery (LLETZ), cold knife conization (CKC), laser conization, or ablation.
✕. Those with known history of cervical cancer.

What they're measuring

Accuracy verification

Timeframe: 2023/12

Clinical validity verification

Timeframe: 2027/06

Trial details

NCT IDNCT05613283

SponsorPeking University People's Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07

View on ClinicalTrials.gov More Human Papillomavirus Infection trials